Eli Lilly has stated that the it is freezing salaries because of the "onslaught" of new generics. Does this mean that hitk will share in these new generics?? More likely these are bigger approvals, but hitk has as few in the works (andas OR development). Maybe that is why the price has shown some additional support.
It may mean, also, that some products get a little less attention - what I mean is that, maybe, Roxanne is pressing for more share on flonase. Next year, when they are focusing on other generics, maybe they won't be so "competitive", and let some share go for a higher price.
I think you could see sales go to $400 million in the next two years. Maybe 500. We will see.